KN026 not checked
Shanghai JMT-Bio Inc. · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · KN046
FollowEvery change as it happens, and a Monday email
Trials
41 active
54 in total · 42 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- HER2-positive Gastric Cancer (2 trials), First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, Early or Locally Advanced HER2-positive Breast Cancer, Resectable HER2-positive Breast Cancer, Stomach Cancer
- Main trialPhase 3
- “This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).”In the company’s words, NCT05838066 on ClinicalTrials.gov
- Other names
- IO therapy · Docetaxel · docetaxol · KN046
Other drugs for HER2-positive Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up4
- 16 DecPhase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 30 Jun 2032Phase 2/3 trial completes · ClinicalTrials.gov
- 7 Aug 2034Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials54
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Jul 2025 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | |
| Phase 3Active, not recruiting | 16 Dec 2026 | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | |
| Phase 3Recruiting | 7 Aug 2034 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | |
| Phase 2/3Recruiting | Nov 2025 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | |
| Phase 2/3Not yet recruiting | 30 Jun 2032 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | |
| Phase 2Not yet recruiting | 30 Jun 2028 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | |
| Phase 2Unknown | 27 May 2021 | Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer | |
| Phase 2Completed | 12 Jan 2022 | Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors | |
| Phase 2Completed | 31 May 2022 | KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer | |
| Phase 2Unknown | 15 Nov 2022 | Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | |
| Phase 1Completed | 30 Jun 2022 | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer | |
| Phase 1Unknown | 31 Dec 2022 | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer | |
| Phase 3Authorised | not given | Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial | |
| Phase 2Authorised | not given | A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy | |
| Phase 3Authorised | not given | A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC) | |
| Phase 4Authorised | not given | LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES | |
| Phase 2Authorised | not given | CRITICS-II: A multicentre randomized phase II trial of neo‐adjuvant chemotherapy followed by surgery vs. neo‐adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo‐adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer | |
| Phase 2Authorised | not given | Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts | |
| Phase 3Authorised | not given | PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed by chemoradiotherapy compared to standard chemoradiotherapy for locally advanced anal squamous cell carcinoma (T3-4 or N1a, b or c) | |
| Phase 3Authorised | not given | ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | |
| Phase 2Ended | not given | ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39) | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 2Authorised | not given | Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy The PHERGain study. | |
| Phase 2Authorised | not given | Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2 | |
| Phase 4Authorised | not given | A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic Assay | |
| Phase 2Ended | not given | Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) | |
| Phase 2Ended | not given | A phase II randomized trial, non comparative, evaluating chemotherapy associated cisplatin, 5-fluorouracil and docetaxel at adapted doses in patients with locally advanced squamous cell carcinoma | |
| Phase 4Authorised | not given | RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHELIAL CARCINOMA | |
| Phase 2Authorised | not given | The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group | |
| Phase 2Ended | not given | Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT | |
| Phase 2Ended | not given | Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT) | |
| Phase 2Authorised | not given | INTERACT-ION : Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study. | |
| Phase 4Authorised | not given | TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer | |
| Phase 2/3Authorised | not given | DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The IKF-DANTE Trial A Trial of AIO in collaboration with SAKK | |
| Phase 3Authorised | not given | Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne | |
| Phase 2Ended | not given | SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study | |
| Phase 2/3Authorised | not given | rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | |
| Phase 3Ended | not given | RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A randomized phase III joint study of the AIO, ARO and DGAV | |
| Phase 3Authorised | not given | SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less | |
| Phase 3Authorised | not given | GERICO11_Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial | |
| Phase 3Authorised | not given | Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial of the AIO /CAOGI /ACO | |
| Phase 4Authorised | not given | RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC) | |
| Phase 2Authorised | not given | Neoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer - de PANDA trial | |
| Phase 3Authorised | not given | OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women | |
| Phase 3Authorised | not given | NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial | |
| Phase 3Authorised | not given | Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer | |
| Phase 2Authorised | not given | Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial | |
| Phase 2Authorised | not given | A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN | |
| Phase 3Authorised | not given | Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial | |
| Phase 2Authorised | not given | IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma | |
| Phase 2/3Authorised | not given | DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” | |
| Phase 2Authorised | not given | COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial | |
| Phase 2Authorised | not given | Intensified neoadjuvant-aDjuvant management of REsectable esophageal adenocarcInomA: the MultIcentre, phase II, singlE-aRm DREAMER study | |
| Phase 2Authorised | not given | ATTENUATION2 - A multicenter, randomized phase II study of the efficacy and safety of de-escalation versus standard adjuvant treatment in patients with low-risk localized gastroesophageal adenocarcinoma (PRODIGE99/FRENCH 39 study). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026